The recent upheaval in the financial markets due to tariff implementations has revealed a stark truth about the nature of wealth, trust, and long-term planning. High-net-worth investors, often perceived as paragons of patience and stability, are not entirely immune to the whims of political turmoil. Instead, their reactions showcase a complicated dance between confidence and
0 Comments
Novo Nordisk’s recent decision to offer its renowned weight-loss drug, Wegovy, via its direct-to-consumer pharmacy, NovoCare, represents a groundbreaking shift in the pharmaceutical landscape. For a cash price of just $499 a month, significantly lower than the usual $1,350, this initiative targets a substantial demographic of underinsured patients. The move acknowledges the immense strain that
0 Comments